638 related articles for article (PubMed ID: 29478739)
1. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
[TBL] [Abstract][Full Text] [Related]
2. Treatment of clinical T2N0M0 esophageal cancer.
Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
[TBL] [Abstract][Full Text] [Related]
3. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
[TBL] [Abstract][Full Text] [Related]
4. Reliability of clinical nodal status regarding response to neoadjuvant chemoradiotherapy compared with surgery alone and prognosis in esophageal cancer patients.
Dijksterhuis WPM; Hulshoff JB; van Dullemen HM; Kats-Ugurlu G; Burgerhof JGM; Korteweg T; Mul VEM; Hospers GAP; Plukker JTM
Acta Oncol; 2019 Nov; 58(11):1640-1647. PubMed ID: 31397195
[No Abstract] [Full Text] [Related]
5. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.
Visser E; van Rossum PSN; Ruurda JP; van Hillegersberg R
Ann Surg; 2017 Nov; 266(5):863-869. PubMed ID: 28742691
[TBL] [Abstract][Full Text] [Related]
6. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
[TBL] [Abstract][Full Text] [Related]
7. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
[TBL] [Abstract][Full Text] [Related]
8. Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer.
Borggreve AS; Heethuis SE; Boekhoff MR; Goense L; van Rossum PSN; Brosens LAA; van Lier ALHMW; van Hillegersberg R; Lagendijk JJW; Mook S; Ruurda JP; Meijer GJ
Eur Radiol; 2020 Apr; 30(4):1896-1907. PubMed ID: 31822974
[TBL] [Abstract][Full Text] [Related]
9. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
10. Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma.
Kathiravetpillai N; Koëter M; van der Sangen MJ; Creemers GJ; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
Eur J Surg Oncol; 2016 Aug; 42(8):1183-90. PubMed ID: 27134188
[TBL] [Abstract][Full Text] [Related]
11. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
[TBL] [Abstract][Full Text] [Related]
12. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
[TBL] [Abstract][Full Text] [Related]
14. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.
Dittrick GW; Weber JM; Shridhar R; Hoffe S; Melis M; Almhanna K; Barthel J; McLoughlin J; Karl RC; Meredith KL
Ann Surg Oncol; 2012 May; 19(5):1678-84. PubMed ID: 22045465
[TBL] [Abstract][Full Text] [Related]
15. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
Anderegg MCJ; van der Sluis PC; Ruurda JP; Gisbertz SS; Hulshof MCCM; van Vulpen M; Mohammed NH; van Laarhoven HWM; Wiezer MJ; Los M; van Berge Henegouwen MI; van Hillegersberg R
Ann Surg Oncol; 2017 Aug; 24(8):2282-2290. PubMed ID: 28424936
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
17. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.
Markar SR; Gronnier C; Pasquer A; Duhamel A; Beal H; Théreaux J; Gagnière J; Lebreton G; Brigand C; Meunier B; Collet D; Mariette C;
Eur J Cancer; 2016 Mar; 56():59-68. PubMed ID: 26808298
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy.
Hulshoff JB; Faiz Z; Karrenbeld A; Kats-Ugurlu G; Burgerhof JG; Smit JK; Plukker JT
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1301-9. PubMed ID: 26314875
[TBL] [Abstract][Full Text] [Related]
19. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
Nomura M; Oze I; Kodaira T; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Tachibana H; Uemura N; Tajika M; Niwa Y; Muto M; Muro K
Int J Clin Oncol; 2016 Oct; 21(5):890-898. PubMed ID: 26980212
[TBL] [Abstract][Full Text] [Related]
20. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]